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Pathological cardiac remodeling 
A B S T R A C T   
Background: Mesenchymal stem cell therapy improves ischemic heart failure via incompletely understood 
mechanisms. C1q-TNFα related protein-9 (CTRP9) is a novel anti-oxidative cardiokine capable of improving the 
local microenvironment and cell survival by its c-terminal active globular domain (gCTRP9). The current study 
attempted to: 1) identify active gCTRP9 c-terminal polypeptides with stem cell protective function; 2) determine 
whether a lead polypeptide may enable/enhance cortical bone-derived mesenchymal stem cell (CBSC) car-
dioprotection against post-myocardial infarction (post-MI) remodeling; and 3) define the responsible underlying 
cellular/molecular mechanisms. 
Methods and results: Utilizing I-TASSER structure prediction and 3-D active site modeling, we cloned and purified 
3 gCTRP9 fragments (CTRP9-237, CTRP9-277, and CTRP9-281). Their activation of cell salvage kinase was 
compared against gCTRP9. Among the three fragments, CTRP9-281 (a 45 residue-containing polypeptide) 
exerted comparable or greater ERK1/2 activation compared to gCTRP9. Treatment with CTRP9-281 or gCTRP9 
significantly increased CBSC proliferation and migration, and attenuated oxidative stress-induced CBSC 
apoptosis. CTRP9-281 and gCTRP9 comparably upregulated SOD2 and SOD3 expression. However, CTRP9-281, 
not gCTRP9, upregulated FGF2 and VEGFA expression/secretion in an ERK1/2 dependent manner. Adminis-
tration of gCTRP9 or CTRP9-281 alone attenuated post-MI cardiac dysfunction and improved CBSC retention in 
the infarcted heart in similar fashion. However, CTRP9-281 exerted greater synergistic effect with CBSC than 
gCTRP9 related to pro-angiogenic, anti-fibrotic, and anti-remodeling effects. Mechanistically, CTRP9-281 
significantly increased SOD2-rich and VEGFA-rich exosome production by CBSC. Exosomes from CTRP9-281 
treated CBSC significantly attenuated oxidative stress-induced cardiomyocyte apoptosis in vitro. An exosome 
generation inhibitor attenuated CTRP9-281 enhancement of CBSC cardioprotection in vivo. 
Conclusion: We identified a CTRP9 polypeptide that upregulates SOD2/SOD3 expression and improves CBSC 
survival/retention, similar to gCTRP9. Moreover, CTRP9-281 stimulates VEGFA-rich exosome production by 
CBSC, exerting superior pro-angiogenic, anti-fibrotic, and cardioprotective actions.   
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1. Introduction 
Cardiovascular disease accounts for the greatest proportion of pre-
mature mortality and morbidity of any noncommunicable disease. 
Ischemic heart disease, such as myocardial infarction, is the largest 
contributor to the epidemic of cardiovascular diseases. Adult mamma-
lian hearts have limited regenerative capacity. A decade’s worth of ev-
idence supports transplantation of mesenchymal stem cells (MSC) as a 
potential therapeutic for ischemic heart failure (IHF) [1,2]. However, 
clinical trials evaluating the efficacy of MSC in patients with acute 
myocardial infarction injury or decompensated IHF have been indeter-
minate [3]. Therapeutic strategies enhancing cell therapy efficacy are in 
great demand. 
The most significant limitation for MSC therapy in IHF remains poor 
retention/survival of engrafted cells [4,5]. MI creates a harsh microen-
vironment with increased oxidative stress, limited nutrients, and oxygen 
dearth, inducing damage and death of delivered cells [6,7]. Overcoming 
this limitation by either promoting MSC survival or improving the local 
Fig. 1. CTRP9-281, a 45 residues-containing polypeptide, possesses cellular salvage kinase activation property and improves CBSC function comparable 
as that of gCTRP9. A/B: Effect of gCTRP9, CTRP9-237, CTRP9-277 and CTRP9-281 (2 μg/mL for 15 min) on cell salvage kinase activation in CBSC. n = 4/group, 
**P < 0.01 vs. vehicle. C: CBSCs proliferation curves (n = 12/group, **P < 0.01 vs. vehicle at indicated time. D/E, Wound healing assay was performed 24 h after 
vehicle, gCTRP9 or CTRP9-281 treatment. n = 6/group *P < 0.05 vs. vehicle. F-I: CBSCs apoptosis was determined by TUNEL staining and caspase cleavage. CBSCs 
were treated with 2 μg/mL gCTRP9 or 2 μg/mL CTRP9-281 for 24h followed by H2O2 for 2 h n = 6/group. *P < 0.05, **P < 0.01 vs. vehicle. DAPI, 4′-6-diamidino-2- 
phenylindole; gCTRP9, globular domain isoform of C1q/tumor necrosis factor–related protein-9; CTRP9-281, 45 residues-containing polypeptides of gCTRP9; O.D., 
optical density; and TUNEL, transferase-mediated dUTP nick-end labeling. 
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environment may help make cell therapy a reality for myocardial 
infarction [8]. The mechanisms underlying MSC activity in injured 
myocardium have been extensively studied. Although it was once 
believed that MSCs could generate new cardiac tissue, evidence now 
demonstrates de novo cardiomyocyte regeneration does not occur after 
MSC administration. The cardioprotective effects of MSC are attributed 
to secretion of immunomodulatory, anti-autophagic, anti-apoptotic, and 
pro-angiogenic factors [9–11]. Molecules capable of improving the MSC 
cardioprotective secretome may enhance cell therapy efficacy against 
IHF. 
The C1q/TNF-related proteins (CTRPs) are a protein family consist-
ing of fifteen (CTRP1-CTRP15) identified adiponectin paralogs [12]. We 
and others recently demonstrate that CTRP9 is a cardiokine, as it has the 
greatest expression level in the adult heart [13–15]. MI significantly 
inhibits myocardial CTRP9 (both mRNA and protein) expression, and 
reduces plasma CTRP9 levels [16,17]. CTRP9 is critical in maintaining a 
healthy local environment in the ischemic heart, enhancing intra-
myocardial injected adipocyte MSC (ADSC) survival, enabling their 
cardioprotection [5]. Importantly, the c-terminal globular domain iso-
form of CTRP9 (gCTRP9, residues 197-333), but not full length CTRP9, 
activates key cell salvage kinases and functions as the active car-
dioprotective isoform [13,18]. However, whether there exist c-terminal 
polypeptides retaining g-CTRP9 activity remains unclear. Producing 
biologically active proteins is difficult, and optimizing the dosage and 
route of recombinant protein administration is complex. Designing 
active CTRP9 polypeptides is a highly desirable strategy in realizing the 
beneficial effects of CTRP9. 
Therefore, the aims of the present study were 1) investigating 
whether gCTRP9-derived polypeptides may exert similar or better stem 
cell protective function than gCTRP9; 2) determining whether a lead 
polypeptide may enable/enhance CBSC cardioprotection against post- 
MI pathological remodeling, and 3) defining the underlying cellular/ 
molecular mechanisms. 
2. Methods 
2.1. CBSCs isolation, identification, and in vitro studies 
CBSCs were isolated from male enhanced green fluorescent protein 
transgenic mice (The Jackson Laboratory) or littermate C57BL/6J con-
trol mice as previously reported (Supplement Figure IA). Cells were 
cultured in Dulbecco’s Modified Eagle Medium-F12-10% FBS. The pas-
sage 2 CBSCs were tested for surface marker expression by flow 
cytometry (BD LSR Fortessa) and differentiation potential. Passage 2 
CBSCs express mesenchymal stem cells markers (such as CD105, Scal-1, 
C-kit, and CD29), but not hematopoietic lineage marker CD45, or 
endothelial cell marker CD31 (Supplemental Fig. 1A and 1B). Their 
adipogenic and osteoblastic potential affirm pluripotency (Supple-
mental Figure 1C). 
2.2. Animal study protocol 
All experiments were performed in adherence to the National In-
stitutes of Health Guidelines on the Use of Laboratory Animals and were 
approved by the Thomas Jefferson University Committee on Animal 
Care. Permanent MI surgery was performed in adult male C57BL/6J 
mice by ligating the left anterior descending coronary artery. Immedi-
ately after MI, 1 × 105 enhanced green fluorescent protein CBSCs sus-
pended in 25 μL PBS (containing 0.2 mM EDTA, pH = 7.3) were 
administered via intramyocardial injection to the infarct border zone at 
3 different sites. 30 min after MI, vehicle, g-CTRP9 (0.25 μg/g/d), or 
CTRP9-281 (0.25 μg/g/d) was administrated via osmotic pump (peri-
toneal implant) for 2 weeks. The number of CBSCs engrafted to the heart 
1 and 3 days after transplantation was determined via green fluorescent 
protein (GFP) immunostain as previously reported [5]. 6 weeks after MI, 
cardiac function was evaluated via echocardiography followed by strain 
analysis. Fibrosis was evaluated by Masson’s trichrome staining. More 
detailed materials and methods are presented in the online-only Data 
Supplement. 
2.3. Statistical analysis 
Data are reported as mean ± SEM. The Kaplan-Meier survival curves 
were analyzed by a Gehan-Breslow-Wilcoxon test. For analysis of dif-
ferences between 2 groups, the unpaired Student t-test was performed. 
For multiple groups, 1-way ANOVA was performed, followed by Bon-
ferroni post hoc test. For multiple groups over time or for testing the 
interaction of CTRP9/CBSC therapy on heart function after MI, 2-way 
ANOVA was performed, followed by Bonferroni post hoc test. P 
values < 0.05 were considered significant. In this study, n is the number 
of animals or cell cultures tested. 
3. Results 
3.1. Identification of a CTRP9 polypeptide activating cellular salvage 
kinases, improving CBSC function via novel mechanism 
We and others have previously demonstrated that gCTRP9 (residues 
197-333) is the active isoform of CTRP9. To maximize CTRP9 trans-
lational application, we attempted to identify gCTRP9 polypeptides with 
capability of activating protective intracellular signaling. Based on the I- 
TASSER structure prediction and three dimensional modeling of the 
active site using cofactor and coach [19], we cloned and purified 3 
gCTRP9 fragments (CTRP9-237, CTRP9-277, and CTRP9-281, patent 
pending). In a recent study, we demonstrate that gCTRP9 kinase acti-
vation is cell-type dependent [5]. Specifically, gCTRP9 activates multi-
ple cell salvage kinases, including ERK1/2, Akt, and AMPK in adult 
cardiomyocyte via binding with AdipoR1. However, AdipoR1 expres-
sion is low in mesenchymal stem cells and gCTRP9 activates ERK1/2 
(not Akt and AMPK) in ADSC via binding with N-cadherin [5]. To 
determine whether CTRP9 fragments retain gCTRP9 kinase activation 
profile, we compared the effect of gCTRP9 fragments upon cell salvage 
kinases against gCTRP9. In H9C2 cells, CTRP9 fragments activated all 
three cell salvage kinases similar as gCTRP9 (data not shown). More 
importantly, all three CTRP9 fragments significantly and selectively 
activated ERK1/2 in CBSC, a property shared with their parent protein, 
gCTRP9 (Fig. 1A and B). Among these three fragments, CTRP9-281 ex-
erts the best ERK1/2 activation (although not statistically different). 
Importantly, CTRP9-281 is the shortest fragment and qualifies as a 
polypeptide (45 aa residue). Finally, no cardiovascular cytotoxic effect 
(including blood pressure, heart rate, left ventricular function, and 
hs-cTnT) was observed after bolus administration of CTRP9-281 at 5-50 
μg/g (tail vein). CTRP9-281 was therefore our prime molecule of 
investigation concerning CBSC function and synergistic car-
dioprotection. We have recently demonstrated that gCTRP9 signifi-
cantly improves ADSC function. To determine whether CTRP-281 (a 
polypeptide with better translational value) may improve CBSC (a stem 
cell type investigated clinically) function, we examined the effect of 
CTRP9-281 upon CBSC proliferation, migration, and oxidative 
stress-induced apoptosis. CTRP9-281 increased CBSC proliferation to 
slightly greater extent compared to gCTRP9 (Cell Counting Kit assay, 
Fig. 1C). Treatment of CBSC for 14 h with either CTRP9-281 or gCTRP9 
significantly enhanced migratory capacity (wound healing assay, 
Fig. 1D/E). Finally, CTRP9-281 and gCTRP9 exerted a comparable 
anti-apoptotic (H2O2, 100 μm for 2 h) effect (TUNEL assay, Fig. 1F/G; 
caspase cleavage, Fig. 1H/I). 
The aforementioned results demonstrate CTRP9-281 exerts similar 
or greater CBSC protection compared to gCTRP9. We next investigated 
whether CTRP9-281 exerts its CBSC protective effect by similar or 
distinctive mechanisms compared to gCTRP9. 23 mRNAs known to 
involved in cell proliferation, migration, and survival were determined 
by qT-PCR. Consistent with our recent report, gCTRP9 altered multiple 
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genes, with SOD2, SOD3, and Mmp9 being the three genes most signif-
icantly upregulated (Fig. 2A and B). Similar to gCTRP9, CTRP9-281 
upregulated these three anti-oxidative/pro-migratory genes (Fig. 2A 
and B). Interestingly, we observed that CTRP9-281 had a unique prop-
erty not shared by gCTRP9. CTRP9-281, not gCTRP9, significantly 
upregulated vascular endothelial growth factor A (Vegfa) and basic 
fibroblast growth factor (bFgf/Fgf2) (Fig. 2A and B). Western blots 
analysis (Fig. 2C and D) and immunocellullar fluorescence analysis 
(Fig. 2E and F) confirmed that CTRP9-281 significantly upregulated 
VEGFA and FGF2 proteins expression. 
The results presented in Fig. 1A and B demonstrated that CTRP9-281 
significantly activated ERK1/2 in CBSC. To clarify the causative role of 
ERK1/2 activation in CTRP9-281 gene/protein upregulation, we deter-
mined the effect of ERK1/2 inhibitor upon CTRP9-281 upregulation of 
pro-angiogenic proteins. ERK1/2 inhibition with U0126 (10 μM, 2 h 
before CTRP9-281 treatment) virtually abolished the effect of CTRP9- 
281 upon pro-angiogenic protein expression (Fig. 2G and H). 
Taken together, these results demonstrate that CTRP9-281 is a bio-
logically active polypeptide capable of upregulating anti-oxidant/pro- 
angiogenic gene expression in an ERK1/2-dependent fashion, 
Fig. 2. Effect of CTRP9-281 gCTRP9 upon anti-oxidative and pro-angiogenic gene expression. A/B: Gene expression profile of CBSCs treated with vehicle, 
gCTRP9, or CTRP9-281 (2 μg/ml, 24 h). n = 3/group. *P < 0.05. C/D, Western blots and quantification of protein expression in CBSCs cell lysis. N = 6/group, *P <
0.05. E/F, CBSCs (green) were fixed in vitro and immune-stained against VEGFA and FGF-2 (red). Nuclei are labeled with 4‘,6-diamidino-2-phenylindole (blue) and 
scale bars, 10 μm. G/H: Western blots and quantification of VEGFA and FGF-2 in CBSCs cell lysis demonstrate that U0126 (an ERK1/2 activation inhibitor) blocked 
CTRP9-281 induced VEGFA and FGF-2 expression (U0126: 10 μM 2 h before CTRP9-281 treatment) n = 4–5/group, *P < 0.05, **P < 0.01. (For interpretation of the 
references to colour in this figure legend, the reader is referred to the Web version of this article.) 
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significantly improving CBSC function and survival. 
3.2. CTRP9-281 enhances CBSC retention, promotes angiogenesis, and 
exerts greater synergistic cardioprotection 
Our pilot experiments demonstrated that administration of gCTRP9 
and CTRP9-281 alone (without CBSC) had similar protective effect 
(Supplement Figure 2). Having demonstrated that CTRP9-281 stimu-
lates VEGFA/FGF2 release by CBSC (in addition to a comparable effect 
on anti-oxidant molecular expression shared with gCTRP9), we next 
investigated whether CTRP9-281 may enhance CBSC cardioprotection 
to greater degree than gCTRP9. First, the effect of CTRP9-281 and 
Fig. 3. Effect of CTRP9-281 and gCTRP9 upon CBSC retention, angiogenesis, and fibrosis after MI. A/B: CTRP9-281 and gCTRP9 comparably increased CBSCs 
survival in peri-infarct area 1 and 3 days after MI. EGFP CBSCs in the peri-infarct area was determined by the number of GFP positive cells per total nuclei (n = 20 
from 4 mice). *P < 0.05; NS: not significant. C/D, CTRP9-281 plus CBSCs-treated animals have increased von Willebrand Factor + blood vessels near the infarct 
border zone by 6 weeks post-MI. Slides from animals receiving MI + vehicle, MI + CBSC or MI + CBSC + gCTRP9 or MI + CBSC + CTRP9-281 injection were stained 
for von Willebrand factor (purple) and α-sarcomeric actin (red). Nuclei are labeled with DAPI (blue) (n = 30 from 6 mice). *P < 0.05. E/F: Masson’s trichrome 
staining revealed that the cardiac fibrotic area was significantly reduced by CBSC + CTRP9-281administration compared with MI group and CBSC + gCTRP9+. n =
6–9/group, *P < 0.05. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) 
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gCTRP9 upon CBSC retention, pro-angiogenic, and anti-fibrotic effects 
were determined. CTRP9-281 increases CBSC retention to similar extent 
as gCTRP9 (Fig. 3A and B). However, CTRP9-281 promoted CBSC 
angiogenic (Fig. 3C/D) and anti-fibrotic effects (Fig. 3E and F) signifi-
cantly greater than gCTRP9. Second, to determine whether the 
enhanced pro-angiogenic and anti-fibrotic effects result in increased 
cardioprotection, the effect of CTRP9-281 and gCTRP9 upon CBSC 
cardiac function was determined by echocardiography followed by 
strain analysis. Consistent with our previous report utilizing ADSC, 
CBSC + gCTRP9 significantly improved cardiac function, as evidenced 
by greater improvement of radial strain and longitudinal strain 
(Fig. 4A–C). Importantly, CBSC + CTRP9-281 improved cardiac function 
to greater degree than gCTRP9 (Fig. 4A–C). Third, we determined the 
impact of CTRP9-281 and gCTRP9 upon CBSC-mediated survival and 
remodeling effects. Compared to vehicle treated animals, CBSC +
gCTRP9 treatment significantly improved survival rate (Fig. 4D), 
increased LVEF (Fig. 4E), reduced heart weight/body weight ratio 
(Fig. 4F), and decreased lung weight/body weight ratio (Fig. 4G). More 
importantly, CBSC + CTRP9-281 treatment markedly improved survival 
rate, increased LVEF, and reduced lung weight/body weight ratio, to 
greater extent than CBSC + gCTRP9 (P < 0.05, Fig. 4A-E/G). CBSC +
CTRP9-281 treatment reduced heart weight/body weight ratio to 
Fig. 4. CBSC þ CTRP9-281 exerts greater synergetic cardioprotection superior to CBSC þ gCTRP9. A/B: Representative echocardiographic images (A = M 
mode, B=B mode) 6 weeks after MI. Three-dimensional regional wall strain diagrams showing contraction (orange/positive values) or relaxation (blue/negative 
values) of 3 consecutive cardiac cycles. C: Strain analysis results of long-axis B-mode images. n = 10–12/group. *P < 0.05, **P < 0.01. D: Survival curves (n = 12/ 
group for sham and 27-45/group for MI). *P < 0.05, **P < 0.01. E: Left ventricular ejection fraction (LVEF), n = 10–18/group**P < 0.01. F: Heart weight/body 
weight ratio (HW/BW). *P < 0.05, **P < 0.01. G: Lung weight/body weight ratio (LW/BW), n = 10–18. *P < 0.05, **P < 0.01. Survival curves were analyzed by 
Gehan-Breslow-Wilcoxon test. LVEF were analyzed with 2-way ANOVA followed by a Bonferroni post hoc test. Other data were analyzed with 1-way ANOVA 
followed by Bonferroni post hoc test. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) 
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greater extent than CBSC + gCTRP9 (although not statistically signifi-
cant, Fig. 4F). Collectively, these results demonstrate CTRP9-281 has 
greater synergistic cardioprotective effect with CBSC than gCTRP9, 
likely due to its VEGF production/angiogenic properties. 
3.3. CTRP9-281 increases SOD2/VEGFA-enriched exosome biogenesis by 
CBSC, contributing to its cardioprotective action 
Our results demonstrate CTRP9-281 is uniquely pro-angiogenic, 
contributing to its synergistic protective effect with CBSC. Consider-
able evidence exists that cancer cells promote angiogenesis and tumor 
growth by releasing VEGF-rich exosomes [20]. To determine whether 
exosomes are involved in CTRP9-281-enhanced CBSC angiogenesis and 
cardioprotection, several experiments were performed. First, the effect 
of gCTRP9 and CTRP9-281 upon CBSC (1 × 106/well) exosome pro-
duction was determined by Nanosight300 and Red fluorescence 
labeled-HRS (hepatocyte growth factor-regulated tyrosine kinase sub-
strate, a multivesicular body marker). CTRP9-281 increases exosome 
numbers to greater extent than gCTRP9 (Fig. 5A and B). Neither gCTRP9 
nor CTRP9-281 significantly altered exosome size (Fig. 5A). Second, 
previous studies demonstrate that ERK1/2 regulates exosome biogenesis 
[21]. We therefore investigated the effect of U0126 (10 mM, 2 h before 
gCTRP9 or CTRP9-281 treatment) upon CBSC exosome production by 
surrogate exosome markers, including CD9, TSG101, Flot, and CD63. 
Although CTRP9-281 stimulated exosomes greater than gCTRP9, 
pre-treatment with U0126 equally blocked such effects (Fig. 5C/D). 
Third, to determine whether VEGFA is carried by CBSC-derived exo-
somes (as observed in cancer cells [20]), exosomes were isolated from 
vehicle-, gCTRP9-, or CTRP9-281-treated CBSC. Both gCTRP9 and 
CTRP9-281 significantly increased exosomes containing SOD2/SOD3. 
CTRP9-281, but not gCTRP9, significantly increased VEGFA levels in 
CBSC-derived exosomes (Fig. 5E/F). 
In a final attempt to determine the role of exosomes in CTRP9-281- 
mediated enhancement of CBSC cardioprotection, two additional ex-
periments were performed. First, adult cardiomyocytes were treated 
with exosomes isolated from vehicle, gCTRP9, or CTRP9-281 treated 
CBSC. Their effect upon H2O2 (100 μM for 2 h) induced apoptosis was 
determined. Exosomes isolated from CTRP9-281 treated CBSC exerted 
superior anti-apoptotic effect compared to that from gCTRP9 treated 
CBSC (Fig. 6A). Second, CBSC was pre-treated with GW4869 (an exo-
some biogenesis inhibitor) before intramyocardial injection. GW4869 
pre-treatment significantly attenuated CBSC + CTRP9-281 car-
dioprotection, as determined by cardiac fibrosis (Fig. 6B) and function 
(Fig. 6C and D). Taken together, these results provide evidence that 
exosomes derived from CTRP9-281 pre-treated CBSCs contribute to 
CBSC cardiac protection. 
4. Discussion 
Three novel observations are notable in the current study. First, we 
identified the first CTRP9 c-terminal polypeptide (CTRP9-281) pos-
sessing similar or greater activity than the native cleaved c-terminal 
globular domain of CTRP9 (gCTRP9) in improving CBSC function. Sec-
ond, we provided the first in vivo evidence that CTRP9-281 in concert 
with CBSC exerts more synergistic cardioprotective effect than gCTRP9 
plus CBSC, likely due to CTRP9-281’s unique promotion of CBSC VEGFA 
production and resultant angiogenesis. Third, we demonstrated that 
exosomes play a critical role in mediating CBSC-endothelial cell and 
CBSC-cardiomyocyte communications, protecting the heart against 
post-MI pathologic remolding (Fig. 7). 
CTRP9 was initially discovered in adipocytes during efforts to 
identify paralogs of adiponectin, an adipocyte-specific cytokine most 
extensively investigated for its metabolic and cardioprotective actions 
[22,23]. However, we and others recently demonstrate that CTRP9 is a 
cardiokine, rather than an adipokine [14,15]. The adult heart expresses 
the highest levels of CTRP9 of any organ, and CTRP9 is central in 
maintaining local microenvironmental homeostasis. A recent study of 
176 HF patients with 3-year follow-up demonstrates the association 
between reduced plasma CTRP9 levels and increased mortality [24]. 
Experimental studies consistently demonstrate that plasma CTRP9 level 
is significantly reduced in post-MI animals [25–30]. CTRP9KO signifi-
cantly exacerbates post-MI pathological remolding [5]. Conversely, 
CTRP9 supplementation attenuates acute ischemia/reperfusion injury, 
post-MI pathologic ventricular remodeling, and IHF [14,27,28]. More-
over, our recent study demonstrates that CTRP9 circulates in the plasma 
primarily in the C-terminal globular domain isoform (gCTRP9) [31]. 
More importantly, gCTRP9, but not full length CTRP9, activates key 
cardiac survival kinases, underlining the biologic importance of pro-
teolytic cleavage of CTRP931. Finally, we recently demonstrate that 
CTRP9 is critical in maintaining a healthy local environment in the 
ischemic heart, enhancing survival of intramyocardial injected stem 
cells, enabling their cardioprotection [5]. Collectively, strong and 
consistent evidence from clinical observations and animal studies sup-
ports CTRP9 as a cardioprotective cardiokine. However, the trans-
lational application of gCTRP9 is limited due to difficulties in producing 
biologically active protein and optimizing recombinant protein admin-
istration dosage and route. Utilizing I-TASSER structure prediction and 
3-D active site modeling followed by functional assays, we discovered a 
CTRP9 C-terminal polypeptide retained biological activity similar to 
gCTRP9. Similar to gCTRP9, CTRP9-281 upregulates antioxidative 
molecules. additionally, CTRP9-281 upregulates pro-angiogenic gene 
expression, significantly improving CBSC function and survival. 
Stem cell therapy for the repair of damaged myocardium has evolved 
into a promising treatment for ischemic heart disease. MSC-based 
therapy, originating from bone marrow, adipose tissue, or umbilical 
cord cells, continues to gain consent and appeal because of the large 
body of preclinical evidence supporting greater paracrine cardiorepar-
ative potential. However, poor survival of donated stem cells and failure 
of stem cell engraftment in the damaged organ pose significant chal-
lenges. Increased understanding of the mechanisms enhancing stem cell 
migration and survival in the microenvironment of the injured 
myocardium is imperative to improve both cell repair capacity and 
therapeutic application strategies. We recently demonstrate that CTRP9 
is critical in maintaining a healthy microenvironment, facilitating ADSC 
engraftment in infarcted myocardial tissue and enhancing ADSC car-
dioprotective efficacy. Specifically, CTRP9KO markedly impaired ADSC 
survival/retention, whereas gCTRP9 supplementation improves ADSC 
survival/retention, protecting against post-MI remodeling [5]. In the 
present study, we demonstrated that although CTRP9-281 has similar 
potency to gCTRP9 in improving CBSC survival and retention, 
CTRP9-281 has greater synergistic protective effect with CBSC than 
gCTRP9. Mechanistic investigation demonstrates that CTRP9-281 
Fig. 5. CTRP9-281 increases VEGF-enriched exosome biogenesis by CBSC. A: Nanosight test the number and size distribution of exosomes derived from the 
CBSCs after PBS, gCTRP9 (2 μg/ml) and CTRP9-281 (2 μg/ml) treatment for 24 h n = 10–12/group, *P < 0.05, **P < 0.01. B: gCTRP9 and CTRP9-281 increase the 
exosome biogenesis as evidenced by increased multivesicular body (MVBs) formation. CBSC were transfected with pCS2 hepatocyte growth factor-regulated tyrosine 
kinase substrate (HRS)-RFP plasmid. Cells were treated with vehicle, gCTRP9 or CTRP9-281 for 24 h. The HRS-RFP positive MVBs were significantly increased in 
CBSCs treatment with gCTRP9 and CTRP9-281 (n ≥ 5, One-Way ANOVA, **p < 0.01). C/D: Western blot showed the Exosome marker protein expression in CBSC 
after gCTRP9 (2 μg/ml) and CTRP9-281(2 μg/ml) treatment for 24 h. U0126 (an ERK1/2 activation inhibitor) blocked CTRP9-281 and gCTRP9-induced exosome 
biogenesis (U0126: 10 μM 2 h before CTRP9-281 treatment; n = 4–5/group). E: Western blot analysis of VEGFA, SOD2 and SOD3 expression in exosomes isolated 
from vehicle, gCTRP9 and CTRP9-281 treated CBSC (1 × 106/well). n = 8/group, *P < 0.05 vs. vehicle. F. Western blot analysis of VEGFA, SOD2 and SOD3 
expression in equal number of exosomes. n = 6/group. 
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stimulation of VEGFA production by CBSC and the resultant 
pro-angiogenic effect is likely responsible for the augmented car-
dioprotective function of CTRP9-281. 
Although it was once believed that mesenchymal stem cells could 
generate new cardiac tissue, evidence now suggests that mesenchymal 
stem cell therapy releases cardioprotective factors which activate 
endogenous pathways, facilitating myocardial repair-not de novo 
cardiomyocyte generation [32]. Recent studies demonstrate these fac-
tors may cluster into extracellular vesicles, particularly exosomes, which 
transfer proteins, microRNAs, and lipids to cardiomyocytes, mediating 
cardioprotection [33,34]. Unfortunately, the reparative capacity of 
mesenchymal stem cells significantly declines post-MI, as these cells 
from post-MI patients possess decreased cardioprotective capability 
[35–37]. Strategies capable of improving the reparative secretome will 
Fig. 6. Exosomes mediate gCTRP9/CTRP9-281 enhancement of CBSC cardioprotection. A: Western blots and quantification protein expression utilizing adult 
mouse cardiomyocytes cell lysis. Cardiomyocytes were treated with exosomes isolated from gCTRP9 or CTRP9-281 treated CBSCs for 24h followed by H2O2 
treatment for 2 h *P < 0.05, **P < 0.01. B-D: CBSC were pre-treated with neutral sphingomyelinase-2 (nSMase2) inhibitor GW4869 (2 μg/ml) before their 
intramyocardial injection. GW4869 attenuated the synergistic anti-fibrotic (B) and cardiac functional improvement (C/D) effect of CTRP9-281 and CBSC. n = 6–10/ 
group, *P < 0.05. 
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restore mesenchymal stem cell cardioreparative capability. Moreover, 
defining the paracrine mechanisms mediating the beneficial effects of 
mesenchymal stem cell therapy may lead to clinically attractive cell-free 
therapeutic options. Our current study demonstrated that treatment of 
CBSC with CTRP9-281 significantly increases SOD-rich and VEGFA-rich 
exosome production. Treatment with exosomes isolated from 
CTRP9-281 pre-treated CBSC significantly attenuated oxidative 
stress-induced cardiomyocyte death. Moreover, pre-treatment of CBSC 
with exosome biogenesis inhibitor abolished the synergistic effect of 
CBSC and CTRP9-281. These results are consistent with the notion that 
cancer cells promote angiogenesis and tumor growth via VEGF-rich 
exosomes [20]. 
It should be noted that although both gCTRP9 and CTRP9-281 
significantly activate ERK1/2, CTRP-281, not gCTRP9, upregulates 
Vegfa and Fgf2 expression. Mechanisms responsible for this differential 
signaling effect are likely complex and requires extensive molecular/ 
cellular/in vivo investigations. One possible explanation is that addi-
tional signaling steps are present between ERK1/2 activation and Vegfa 
and Fgf2 expression. CTRP9-281, not gCTRP9, may activate the mole-
cules required for ERK1/2-mediated Vegfa and Fgf2 expression. This 
possibility will be investigated in our future study. 
In summary, we identified the first CTRP9 c-terminal polypide 
(CTRP9-281) with strong biological activity. It shares the anti-oxidant/ 
cell survival effects with gCTRP9, promoting CBCS retention after 
intramyocardial injection. Additionally, CTRP9-281 promotes VEGFA- 
rich exosome production from CBSC, and exerts augmented angio-
genic and cardioprotective effect when co-administered with CBSC in 
the infarcted heart. Collectively, these results demonstrate that CTRP9- 
281 may have important translational value in mesenchymal stem cell 
therapy against ischemic cardiac injury. 
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